TY - JOUR
T1 - Intratumoral delivery of plasmid IL12 via electroporation leads to regression of injected and noninjected tumors in Merkel cell carcinoma
AU - Bhatia, Shailender
AU - Longino, Natalie V.
AU - Miller, Natalie J.
AU - Kulikauskas, Rima
AU - Iyer, Jayasri G.
AU - Ibrani, Dafina
AU - Blom, Astrid
AU - Byrd, David R.
AU - Parvathaneni, Upendra
AU - Twitty, Christopher G.
AU - Campbell, Jean S.
AU - Le, Mai H.
AU - Gargosky, Sharron
AU - Pierce, Robert H.
AU - Heller, Richard
AU - Daud, Adil I.
AU - Nghiem, Paul
N1 - Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Purpose: IL12 promotes adaptive type I immunity and has demonstrated antitumor efficacy, but systemic administration leads to severe adverse events (AE), including death. This pilot trial investigated safety, efficacy, and immunologic activity of intratumoral delivery of IL12 plasmid DNA (tavo) via in vivo electroporation (i.t.-tavo-EP) in patients with Merkel cell carcinoma (MCC), an aggressive virus-associated skin cancer. Patients and Methods: Fifteen patients with MCC with superficial injectable tumor(s) received i.t.-tavo-EP on days 1, 5, and 8 of each cycle. Patients with locoregional MCC (cohort A, N = 3) received one cycle before definitive surgery in week 4. Patients with metastatic MCC (cohort B, N = 12) received up to four cycles total, administered at least 6 weeks apart. Serial tumor and blood samples were collected. Results: All patients successfully completed at least one cycle with transient, mild (grades 1 and 2) AEs and without significant systemic toxicity. Sustained (day 22) intratumoral expression of IL12 protein was observed along with local inflammation and increased tumor-specific CD8þ T-cell infiltration, which led to systemic immunologic and clinical responses. The overall response rate was 25% (3/12) in cohort B, with 2 patients experiencing durable clinical benefit (16 and 55þ months, respectively). Two cohort A patients (1 with pathologic complete remission) were recurrence-free at 44þ and 75þ months, respectively. Conclusions: I.t.-tavo-EP was safe and feasible without systemic toxicity. Sustained local expression of IL12 protein and local inflammation led to systemic immune responses and clinically meaningful benefit in some patients. Gene electrotransfer, specifically i.t.-tavo-EP, warrants further investigation for immunotherapy of cancer.
AB - Purpose: IL12 promotes adaptive type I immunity and has demonstrated antitumor efficacy, but systemic administration leads to severe adverse events (AE), including death. This pilot trial investigated safety, efficacy, and immunologic activity of intratumoral delivery of IL12 plasmid DNA (tavo) via in vivo electroporation (i.t.-tavo-EP) in patients with Merkel cell carcinoma (MCC), an aggressive virus-associated skin cancer. Patients and Methods: Fifteen patients with MCC with superficial injectable tumor(s) received i.t.-tavo-EP on days 1, 5, and 8 of each cycle. Patients with locoregional MCC (cohort A, N = 3) received one cycle before definitive surgery in week 4. Patients with metastatic MCC (cohort B, N = 12) received up to four cycles total, administered at least 6 weeks apart. Serial tumor and blood samples were collected. Results: All patients successfully completed at least one cycle with transient, mild (grades 1 and 2) AEs and without significant systemic toxicity. Sustained (day 22) intratumoral expression of IL12 protein was observed along with local inflammation and increased tumor-specific CD8þ T-cell infiltration, which led to systemic immunologic and clinical responses. The overall response rate was 25% (3/12) in cohort B, with 2 patients experiencing durable clinical benefit (16 and 55þ months, respectively). Two cohort A patients (1 with pathologic complete remission) were recurrence-free at 44þ and 75þ months, respectively. Conclusions: I.t.-tavo-EP was safe and feasible without systemic toxicity. Sustained local expression of IL12 protein and local inflammation led to systemic immune responses and clinically meaningful benefit in some patients. Gene electrotransfer, specifically i.t.-tavo-EP, warrants further investigation for immunotherapy of cancer.
UR - http://www.scopus.com/inward/record.url?scp=85079021690&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079021690&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-19-0972
DO - 10.1158/1078-0432.CCR-19-0972
M3 - Article
C2 - 31582519
AN - SCOPUS:85079021690
SN - 1078-0432
VL - 26
SP - 598
EP - 607
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 3
ER -